DOCSLIB.ORG

Brand-To-Generic Medication Reference

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brand-To-Generic Medication Reference Brand Name Generic Name Absorica® Capsules Isotretinoin Capsules, USP Acanya® Gel Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% Accutane® Capsules Claravis™ (isotretinoin capsules, USP) Achromycin V® Capsules, USP Tetracycline Hydrochloride Capsules, USP Acticlate® Tablets Doxycycline Hyclate Tablets, USP Actigall® Capsules Ursodiol Capsules, USP ACTIQ® oral transmucosal lozenge Oral Transmucosal Fentanyl Citrate [C-II] (OTFC) Lozenges CII Activella® Tablets, 1 mg/0.5 mg Mimvey® (estradiol and norethindrone acetate tablets, USP) Actonel® Tablets Risedronate Sodium Tablets, USP Actos Tablets Pioglitazone Tablets, USP Adcirca® Tablets ALYQ™ (tadalafil tablets, USP) Adderall XR® Capsules [CII] Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended- Release Capsules CII Adderall® Tablets [CII] Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets CII Adenoscan® Injection Adenosine Injection, USP Adriamycin PFS® Injection Doxorubicin Hydrochloride Injection, USP Afinitor® Tablets Everolimus Tablets Agrylin® Capsules Anagrelide Capsules, USP Brand Name Generic Name AirDuo RespiClick® Inhalation Fluticasone Propionate and Powder Salmeterol Inhalation Powder (Multidose Dry Powder Inhaler) Albenza® Tablets Albendazole Tablets, USP Alesse® Tablets Aviane® (levonorgestrel and ethinyl estradiol tablets, USP) Alkeran® for Injection Melphalan Hydrochloride for Injection Aloxi® Injection Palonosetron Hydrochloride Injection Ambien® Tablets [CIV] Zolpidem Tartrate Tablets, USP CIV Amoxil® Capsules Amoxicillin Capsules, USP Amoxil® Chewable Tablets Amoxicillin Tablets, USP (Chewable) Amoxil® Powder for Oral Amoxicillin for Oral Suspension, USP Suspension Amoxil® Tablets Amoxicillin Tablets, USP Amrix® (Cyclobenzaprine Cyclobenzaprine Hydrochloride Hydrochloride Extended-Release Extended-Release Capsules Capsules) AndroGel® [CIII] Testosterone Gel 1% CIII AndroGel® [CIII] Testosterone Gel 1% CIII AndroGel® 1.62% [CIII] Testosterone Gel, 1.62% CIII AndroGel® 1.62% [CIII] Testosterone Gel, 1.62% CIII AndroGel® 1.62% [CIII] Testosterone Gel, 1.62% CIII Ansaid® Tablets Flurbiprofen Tablets, USP Apriso® Extended-Release Capsules Mesalamine Extended-Release Capsules Aptensio XR® capsules [CII] Methylphenidate Hydrochloride Extended-Release Capsules CII Arimidex® Tablets Anastrozole Tablets Brand Name Generic Name Artane® Tablets Trihexyphenidyl Hydrochloride Tablets, USP Arthrotec® Tablets Diclofenac Sodium and Misoprostol Delayed-Release Tablets Asendin® Tablets Amoxapine Tablets, USP Ativan® Tablets [CIV] Lorazepam Tablets, USP CIV Atripla® tablets Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets Augmentin ES-600® for Oral Amoxicillin and Clavulanate Suspension Potassium for Oral Suspension Augmentin® Chewable Tablets Amoxicillin and Clavulanate Potassium Tablets, USP (Chewable) Augmentin® for Oral Suspension Amoxicillin and Clavulanate Potassium for Oral Suspension, USP Augmentin® Tablets Amoxicillin and Clavulanate Potassium Tablets, USP Avalide® Tablets Irbesartan and Hydrochlorothiazide Tablets, USP Avelox® Tablets Moxifloxacin Hydrochloride Tablets Avinza® Extended-Release Capsules Morphine Sulfate Extended-Release [CII] Capsules, USP CII Avita® Cream Tretinoin Cream, USP Axiron® Topical Solution [CIII] Testosterone Topical Solution CIII Aygestin® Tablets Norethindrone Acetate Tablets, USP AZILECT® Tablets Rasagiline Tablets Azopt® Brinzolamide Ophthalmic Suspension, USP Azulfidine® Tablets Sulfasalazine Tablets, USP Bactroban® Ointment Mupirocin Ointment, USP Brand Name Generic Name Benemid® Tablets Probenecid Tablets, USP Bentyl® Capsules Dicyclomine Hydrochloride Capsules, USP Bentyl® Tablets Dicyclomine Hydrochloride Tablets, USP Betapace® Tablets Sotalol Hydrochloride Tablets, USP Bethkis® Tobramycin Inhalation Solution, USP Biaxin® XL Filmtab® Clarithromycin Extended-Release Tablets, USP BuSpar® Tablets Buspirone Hydrochloride Tablets, USP Butrans® Transdermal System [CIII] Buprenorphine Transdermal System CIII Camptosar® Injection Irinotecan Hydrochloride Injection Canasa® suppositories Mesalamine Suppositories Carafate® Tablets Sucralfate Tablets, USP Cardizem® CD Capsules Cartia XT® (Diltiazem HCl Extended- Release Capsules, USP) Cardizem® CD Capsules Diltiazem Hydrochloride Extended- Release Capsules, USP Cardizem® LA Extended Release Matzim® LA (Diltiazem Tablets Hydrochloride) Extended-Release Tablets Cardizem® Tablets Diltiazem Hydrochloride Tablets, USP Cardura® Tablets Doxazosin Tablets, USP Cataflam® Tablets Diclofenac Potassium Tablets, USP Catapres TTS® Clonidine Transdermal System, USP Catapres® Tablets Clonidine Hydrochloride Tablets, USP Brand Name Generic Name Ceclor® CD Tablets Cefaclor Extended-Release Tablets, USP Cefzil® Tablets Cefprozil Tablets, USP Celebrex® Capsules Celecoxib Capsules CellCept® Capsules Mycophenolate Mofetil Capsules, USP Cephulac® Syrup Enulose Lactulose Solution, USP Chronulac® Syrup Constulose (Lactulose Solution, USP) Cialis® Tablets Tadalafil Tablets, USP Cipro® Tablets Ciprofloxacin Tablets, USP Clinoril® Tablets Sulindac Tablets, USP Clobex® Lotion Clobetasol Propionate Lotion Clobex® Spray Clobetasol Propionate Spray Col-BENEMID® Tablets Probenecid and Colchicine Tablets, USP Colcrys® (colchicine, USP) tablets Colchicine Tablets, USP Concerta® Extended-Release Methylphenidate Hydrochloride Tablets [CII] Extended-Release Tablets, USP CII Condylox® Solution Podofilox Topical Solution Coreg® Tablets Carvedilol Tablets, USP Coumadin® Tablets Warfarin Sodium Tablets, USP Cubicin® Daptomycin for Injection Cuprimine® Capsules Penicillamine Capsules, USP Cyclessa® Tablets Velivet® (desogestrel and ethinyl estradiol tablets, USP - triphasic regimen) Cymbalta® Delayed-Release Duloxetine Delayed-Release Capsules Capsules, USP Cytomel® Tablets Liothyronine Sodium Tablets USP Brand Name Generic Name Danocrine® Capsules Danazol Capsules, USP DDAVP® Injection Desmopressin Acetate Injection, USP DDAVP® Tablets Desmopressin Acetate Tablets Deltasone® Tablets Prednisone Tablets, USP Delzicol® Delayed-Release Capsules Mesalamine Delayed-Release Capsules Demadex® Tablets Torsemide Tablets Demulen® Tablets Kelnor® 1/35 (ethynodiol diacetate and ethinyl estradiol tablets, USP) Demulen® Tablets Kelnor® 1/50 (28 Day Regimen) (ethynodiol diacetate and ethinyl estradiol tablets USP) Depakene® Capsules Valproic Acid Capsules, USP Depo-Medrol® Methylprednisolone Acetate Injectable Suspension, USP Depo-Provera® Contraceptive Medroxyprogesterone Acetate Injection, USP Injectable Suspension, USP Depo-Testosterone® Injection [CIII] Testosterone Cypionate Injection, USP CIII DesOwen® Cream Desonide Cream DesOwen® Lotion Desonide Lotion Desyrel® Tablets Trazodone Hydrochloride Tablets, USP Detrol® LA Tolterodine Tartrate Extended- Release Capsules Detrol® Tablets Tolterodine Tartrate Tablets Dexedrine® Spansule® [CII] Dextroamphetamine Sulfate Extended-Release Capsules CII Dextrostat® Tablets [CII] Dextroamphetamine Sulfate Tablets, USP CII Brand Name Generic Name DiaBeta® Tablets Glyburide Tablets, USP Diclegis® Delayed-Release Tablets Doxylamine Succinate and 10 mg/10 mg Pyridoxine Hydrochloride Delayed- Release Tablets Differin® Gel Adapalene Gel Diflucan® Tablets Fluconazole Tablets, USP Dilaudid-HP® Injection [CII] Hydromorphone Hydrochloride Injection, USP CII Diprivan® Injection Propofol Injection Emulsion, USP Diprolene® Augmented Ointment Betamethasone Dipropionate 0.05% Ointment (Augmented), USP Diprosone® Cream 0.05% Betamethasone Dipropionate Cream, USP Diprosone® Ointment 0.05% Betamethasone Dipropionate Ointment, USP Ditropan® Tablets Oxybutynin Chloride Tablets, USP Dolobid® Tablets Diflunisal Tablets, USP Doryx® Doxycycline Hyclate Delayed- Release Tablets, USP Dostinex® Tablets Cabergoline Tablets, USP DTIC-Dome® Dacarbazine for Injection, USP Duricef® Capsules Cefadroxil Capsules, USP Duricef® Tablets Cefadroxil Tablets, USP Dynacin® Capsules Minocycline Hydrochloride Capsules, USP DynaCirc® Capsules Isradipine Capsules, USP Dynapen® Capsules Dicloxacillin Sodium Capsules, USP EC-Naprosyn® Delayed-Release Naproxen Delayed-Release Tablets, Tablets USP Brand Name Generic Name Effexor XR® Extended-Release Venlafaxine Hydrochloride Capsules Extended-Release Capsules, USP Effexor® Tablets Venlafaxine Tablets, USP Elidel® Cream 1% Pimecrolimus Cream, 1% Elimite® Cream Permethrin Cream Eloxatin® Injection Oxaliplatin for Injection, USP Emla® Cream Lidocaine and Prilocaine Cream, USP Entereg® (alvimopan) capsules Alvimopan Capsules EpiPen® and EpiPen Jr® Auto- Epinephrine Injection, USP (Auto- Injector Injector) ESTRACE® CREAM Estradiol Vaginal Cream, USP, 0.01% Estrace® Tablets Estradiol Tablets, USP Estrostep® Fe Tablets Tri-Legest® Fe 28 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) Evista® Tablets Raloxifene Hydrochloride Tablets, USP Exjade® Tablets for Oral Suspension Deferasirox Tablets for Oral Suspension Famvir® Tablets Famciclovir Tablets FazaClo® Orally Disintegrating Clozapine Orally Disintegrating Tablets Tablets FazaClo® Orally Disintegrating Clozapine Orally Disintegrating Tablets Tablets FazaClo® Orally Disintegrating Clozapine Orally Disintegrating Tablets Tablets Feldene® Capsules Piroxicam Capsules, USP Femara® Tablets Letrozole Tablets, USP Brand Name Generic Name Femhrt® Tablets Jinteli® (norethindrone acetate and ethinyl estradiol tablets, USP) Finacea® Gel, 15% Azelaic Acid Gel, 15% Fioricet® with Codeine
Load more

Recommended publications
  • Pricing Sheet
    Trusted Service. Proven Savings. Pharmacy: (325) 704-5222 Fax: (325) 777-4819 17 Windmill Circle Suite B Abilene, TX 79606 bigcountry.clarxpharmacy.com SureScript ID: 1171544616 Dermatology Compounds UPDATED 9/3/2020 Medication QTY Price Fluorouracil/ Calcipotriene Cream 4.5/ 0.005% 30 g $55 Fluorouracil Cream 4.5% or 1.5% 30 g $50 Wart Peel Cream (Salicylic Acid/ Fluorouracil 17/ 2%) 30 g $45 Ivermectin Lotion 1.5% 30 g $45 Double Rosacea Cream (Metronidazole/ Ivermectin 1/ 1%) 30 g $55 Triple Rosacea Cream (Azelaic Acid/ Metronidazole/ Ivermectin 15/ 1/ 1%) 30 g $45 Azelaic Acid Cream 17% 30 g $45 Calcipotriene/ Clobetasol Cream 0.005/ 0.045% 60 g $85 Clioquinol/ Hydrocortisone Cream 1/ 1% 30 g $55 Tretinoin Micro Cream 0.033/ 0.055/ 0.09% 45 g $55 Clindamycin/ Tretinoin Micro Cream 1/0.03% 30 g $75 Triamcinolone/ Hydroquinone/ Tretinoin Cream 0.025/ 4/ 0.05% 30 g $55 Hydrocortisone/ Hydroquinone/ Tretinoin Cream 2.5/ 8/ 0.05% 30 g $55 Hydroquinone/ Kojic Acid Cream 12/ 6% or 10/ 3% 30 g $65 Hydroquinone/ Tretinoin Cream 4/ 0.05% 30 g $65 Squaric Acid Solution 0.1 / 0.01 / 0.001% 15 ml $85 Urea Cream 35% 90 g $45 Dapsone 6% Cream 60 g $55 Costmetic Numbing Oint. (Lidocain 23%/Tetracain 7%) 60g $35 General topical compound pricing for other compounds QTY Price Variations to the compounds above will fall into the pricing below. One Active Ingredient 30g $79 Two Active Ingredients 30g $89 Three Active Ingredients 30g $99 *This applies to most compounds (90%) not all, if exceptionally expensive we will call the office to discuss* All cash, no rebates or insurance to mess with! Medicare patients get medications at these great prices too! Free Delivery in 3-5 business days for compounds Page 1 Trusted Service.
    [Show full text]
  • 204760Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204760Orig1s000 OTHER REVIEW(S) MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: September 16, 2014 FROM: Julie Beitz, MD SUBJECT: Approval Action TO: NDA 204760 Movantik (naloxegol) tablets AstraZeneca Pharmaceuticals LP Summary Naloxegol is an antagonist of opioid binding at the muͲopioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherallyͲacting opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone and a new molecular entity. Pegylation confers the following properties: naloxegol has reduced passive permeability across membranes compared to naloxone; naloxegol is a PͲglycoprotein (PͲgp) efflux transporter substrate; and naloxegol is orally bioavailable. The reduced passive permeability and PͲgp efflux transporter properties limit CNS entry of naloxegol compared to naloxone. This memo documents my concurrence with the Division of Gastroenterology and Inborn Errors Product’s recommendation for approval of NDA 204760 for Movantik (naloxegol) tablets for the treatment of opioidͲinduced constipation (OIC) in adult patients with chronic nonͲcancer pain. Discussions regarding product labeling, and postmarketing study requirements and commitments have been satisfactorily completed. There are no inspectional issues that preclude approval. Dosing The recommended dose of Movantik (naloxegol) tablets is 25 mg taken once daily in the morning on an empty stomach. Patients who do not tolerate this dose, may reduce the dose to 12.5 mg once daily. Maintenance laxatives should be discontinued prior to initiation of therapy with Movantik.
    [Show full text]
  • Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn
    Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs.
    [Show full text]
  • Opioids in Palliative Care: Evidence Update May 2014
    Opioids in palliative care Evidence Update May 2014 A summary of selected new evidence relevant to NICE clinical guideline 140 ‘Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults’ (2012) Evidence Update 58 Contents Introduction ................................................................................................................................ 3 Key points .................................................................................................................................. 4 1 Commentary on new evidence .......................................................................................... 5 1.1 Communication .......................................................................................................... 5 1.2 Starting strong opioids – titrating the dose ................................................................ 5 1.3 First-line maintenance treatment ............................................................................... 6 1.4 First-line treatment if oral opioids are not suitable – transdermal patches ................ 6 1.5 First-line treatment if oral opioids are not suitable – subcutaneous delivery ............. 7 1.6 First-line treatment for breakthrough pain in patients who can take oral opioids ...... 7 1.7 Management of constipation ..................................................................................... 8 1.8 Management of nausea ..........................................................................................
    [Show full text]
  • January 2021 Update
    PUBLISHED JULY 08, 2021 OCTOBER/DECEMBER 2020; JANUARY 2021 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the update to the Highmark Drug Formularies and pharmaceutical management procedures for January 2021. The formularies and pharmaceutical management procedures are updated on a bimonthly basis, and the following changes reflect the decisions made in October, December, and January by our Pharmacy and Therapeutics Committee. These updates are effective on the dates noted throughout this document. Please reference the guide below to navigate this communication: Section I. Highmark Commercial and Healthcare Reform Formularies A. Changes to the Highmark Comprehensive Formulary and the Highmark Comprehensive Healthcare Reform Formulary B. Changes to the Highmark Healthcare Reform Essential Formulary C. Changes to the Highmark Core Formulary D. Changes to the Highmark National Select Formulary E. Updates to the Pharmacy Utilization Management Programs 1. Prior Authorization Program 2. Managed Prescription Drug Coverage (MRxC) Program 3. Formulary Program 4. Quantity Level Limit (QLL) Programs As an added convenience, you can also search our drug formularies and view utilization management policies on the Provider Resource Center (accessible via NaviNet® or our website). Click the Pharmacy Program/Formularies link from the menu on the left. Highmark Blue Cross Blue Shield Delaware is an independent licensee of the Blue Cross and Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides secure, web-based portal between providers and health insurance companies. IMPORTANT DRUG SAFETY UPDATES 03/31/2021 – Studies show increased risk of heart rhythm problems with seizure and mental health medicine lamotrigine (Lamictal) in patients with heart disease.
    [Show full text]
  • Cream LOTRISONE® Lotion (Clotrimazole and Betamethasone Dipropionate)
    LOTRISONE® Cream LOTRISONE® Lotion (clotrimazole and betamethasone dipropionate) FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE. NOT RECOMMENDED FOR PATIENTS UNDER THE AGE OF 17 YEARS AND NOT RECOMMENDED FOR DIAPER DERMATITIS. DESCRIPTION LOTRISONE® Cream and Lotion contain combinations of clotrimazole, a synthetic antifungal agent, and betamethasone dipropionate, a synthetic corticosteroid, for dermatologic use. Chemically, clotrimazole is 1–(o-chloro-α,α-diphenylbenzyl) imidazole, with the empirical formula C22H17CIN2, a molecular weight of 344.84, and the following structural formula: Clotrimazole is an odorless, white crystalline powder, insoluble in water and soluble in ethanol. Betamethasone dipropionate has the chemical name 9-fluoro-11β,17,21- trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.59, and the following structural formula: 1 LRN# 000370-LOS-MTL-USPI-1 Betamethasone dipropionate is a white to creamy white, odorless crystalline powder, insoluble in water. Each gram of LOTRISONE Cream contains 10 mg clotrimazole and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone), in a hydrophilic cream consisting of purified water, mineral oil, white petrolatum, cetyl alcohol plus stearyl alcohol, ceteareth-30, propylene glycol, sodium phosphate monobasic monohydrate, and phosphoric acid; benzyl alcohol as preservative. LOTRISONE Cream may contain sodium hydroxide. LOTRISONE Cream is smooth, uniform, and white to off-white in color. Each gram of LOTRISONE Lotion contains 10 mg clotrimazole and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone), in a hydrophilic base of purified water, mineral oil, white petrolatum, cetyl alcohol plus stearyl alcohol, ceteareth-30, propylene glycol, sodium phosphate monobasic monohydrate, and phosphoric acid; benzyl alcohol as a preservative.
    [Show full text]
  • Salicylic Acid
    Treatment Guide to Common Skin Conditions Prepared by Loren Regier, BSP, BA, Sharon Downey -www.RxFiles.ca Revised: Jan 2004 Dermatitis, Atopic Dry Skin Psoriasis Step 1 - General Treatment Measures Step 1 - General Treatment Measures Step 1 • Avoid contact with irritants or trigger factors • Use cool air humidifiers • Non-pharmacologic measures (general health issues) • Avoid wool or nylon clothing. • Lower house temperature (minimize perspiration) • Moisturizers (will not clear skin, but will ↓ itching) • Wash clothing in soap vs detergent; double rinse/vinegar • Limit use of soap to axillae, feet, and groin • Avoid frequent or prolonged bathing; twice weekly • Topical Steroids Step 2 recommended but daily bathing permitted with • Coal Tar • Colloidal oatmeal bath products adequate skin hydration therapy (apply moisturizer • Anthralin • Lanolin-free water miscible bath oil immediately afterwards) • Vitamin D3 • Intensive skin hydration therapy • Limit use of soap to axillae, feet, and groin • Topical Retinoid Therapy • “Soapless” cleansers for sensitive skin • Apply lubricating emollients such as petrolatum to • Sunshine Step 3 damp skin (e.g. after bathing) • Oral antihistamines (1st generation)for sedation & relief of • Salicylic acid itching give at bedtime +/- a daytime regimen as required Step 2 • Bath additives (tar solns, oils, oatmeal, Epsom salts) • Topical hydrocortisone (0.5%) for inflammation • Colloidal oatmeal bath products Step 2 apply od-tid; ointments more effective than creams • Water miscible bath oil • Phototherapy (UVB) may use cream during day & ointment at night • Humectants: urea, lactic acid, phospholipid • Photochemotherapy (Psoralen + UVA) Step 4 Step 3 • Combination Therapies (from Step 1 & 2 treatments) • Prescription topical corticosteroids: use lowest potency • Oral antihistamines for sedation & relief of itching steroid that is effective and wean to twice weekly.
    [Show full text]
  • (6337) Smartpharmacy.Com
    Phone 1.877.811.MEDS (6337) Fax 800.910.7195 SmartPharmacy.com Your prescription has been faxed to SMART PHARMACY Fax: (800) 910-7195 Phone: (877) 811-MEDS (6337) ** SHIPPING IS ALWAYS FREE Your physician has prescribed a topical cream to treat your pain and inflammation. Please review the following information about your prescription. HOW DO I FILL MY PRESCRIPTION? HOW DO I APPLY THE CREAM? • In most cases, your physician’s office will fax your The proper application of the cream is imperative to achieve prescription directly to Smart Pharmacy. A Smart Pharmacy maximum results; therefore, be sure to follow directions on the Registered Pharmacy Technician will begin processing your prescription label. prescription and contact you by phone. • Your prescription will arrive in an easy-to-use pump applicator. • Please leave a good contact number for calling or texting in order to expedite your order. • Clean and dry the affected area prior to applying topical cream with each application. • With your approval, the prescription will be shipped directly to your home or business at no charge. • Use latex gloves or thoroughly wash hands before and after each application. Do not apply to open wounds. Do not touch eyes or WILL INSURANCE COVER MY SMART mouth before washing hands as you may cause burning and irritation. PHARMACY PRESCRIPTION? • Most commercial insurance plans cover topical preparations with a reasonable co-pay. • Apply a liberal amount to affected area and rub in well as directed by your physician, massaging the affected area for 1-2 minutes. • Smart Pharmacy will verify your coverage and discuss your co-pay obligation.
    [Show full text]
  • Drugs That Are Not Covered
    Drugs that are Not Covered* Current 10/1/21 In addition to this list, newly marketed prescription medications may not be covered until the Pharmacy & Therapeutics Committee has had an opportunity to review the medication, to determine whether the medication will be covered and if so, which tier will apply based on safety, efficacy and the availability of other products within that class of medications. The current list of newly marketed drugs can be found on our New to Market Drug list. Abilify tablets albuterol HFA inhalers (authorized Apexicon E cream Abilify MyCite tablets generics for ProAir, Proventil, Ventolin Apidra vials Absorica capsules HFA inhalers) Apidra SoloStar injection Absorica LD capsules Aldactone tablets Aplenzin tablets Abstral sublingual tablets Aldara cream Apriso capsules Acanya gel and pump gel Alkindi sprinkle capsules Arava tablets Accupril tablets Allegra Children’s Allergy ODT Arazlo lotion acetaminophen 320.5 mg/caffeine 30 Allegra ODT, suspension and tablets Arestin microspheres mg/dihydrocodeine 16 mg Alltizal tablets Aricept tablets capsulesAciphex tablets alogliptin (authorized generic for Aricept ODT Aciphex Sprinkle capsules Nesina) Arimidex tablets Acticlate tablets alogliptin/metformin tablets (authorized Arixtra injection Active-Prep kits generic for Kazano) ArmonAir Digihaler inhaler Activella tablets alogliptin/pioglitazone (authorized ArmonAir Respiclick inhaler Actonel tablets generic for Oseni) Aromasin tablets Actoplus Met tablets Alphagan P 0.1% eye drops Arthrotec 50 and 75 tablets Actos
    [Show full text]
  • Important Pharmacy Information There Is No Copay When Your Primary Care Provider (PCP) Or Unitedhealthcare Community Plan Specialist Writes You a Covered Prescription
    Important Pharmacy Information There is no copay when your Primary Care Provider (PCP) or UnitedHealthcare Community Plan Specialist writes you a covered prescription. But you can get many over-the-counter (OTC) medicines free when you have a prescription. You can get the medications listed on the following pages when they are medically necessary and you get a written prescription from your UnitedHealthcare Community Plan doctor and take it to a UnitedHealthcare Community Plan pharmacy. To get your medicine: • Take your prescription to a UnitedHealthcare Community Plan pharmacy. To find a pharmacy, call 1-800-903-5253 or go to UHCCommunityPlan.com. • For your safety, we urge you to select a single pharmacy from which to get your drugs. • Get to know the pharmacist and build a relationship. If the UnitedHealthcare Community Plan pharmacy says they cannot fill your covered prescription or you have to pay more than your copay: Do not leave the pharmacy. Do not pay for it yourself. Ask the pharmacy why they cannot fill your prescription. Response Your Solution Not Covered • Ask them to call OptumRx right away to find out which medicine is covered. • Ask them to call your doctor to see if you can get the covered medicine instead. Prior • Ask them to call your doctor for a prior authorization. Authorization • You can call your doctor and ask that a prior authorization be sent to: Needed UnitedHealthcare Pharmacy Prior Notification Service Fax 1-866-940-7328 Phone 1-800-310-6826 Refill Too Soon • Ask what day it can be filled. • Pick your prescription up the day it can be filled.
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
    Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents INTRODUCTION Irritable bowel syndrome (IBS) is a gastrointestinal disorder that most commonly manifests as chronic abdominal pain and altered bowel habits in the absence of any organic disorder (Wald 2017). IBS may consist of diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), IBS with a mixed symptomatology (IBS-M), or unclassified IBS (IBS-U). Switching between the subtypes of IBS is also possible (Ford et al 2014). IBS is a functional disorder of the gastrointestinal tract characterized by abdominal pain, discomfort, and bloating, as well as disturbed bowel habit. The exact pathogenesis of the disorder is unknown; however, it is believed that altered gastrointestinal tract motility, visceral hypersensitivity, autonomic dysfunction, and psychological factors indicate disturbances within the enteric nervous system, which controls the gastrointestinal system (Andresen et al 2008, Ford et al 2009). Prevalence estimates of IBS range from 5 to 15%, and it typically occurs in young adulthood (Ford et al 2014). IBS-D is more common in men, and IBS-C is more common in women (World Gastroenterology Organization [WGO], 2015). Symptoms of IBS often interfere with daily life and social functioning (WGO 2015). The general goals of therapy are to alleviate the patient’s symptoms and to target any specific exacerbating factors (eg, medications, dietary changes), concerns about serious illness, stressors, or potential psychiatric comorbidities that may exist (Wald 2015). Non-pharmacological interventions to combat IBS symptoms include dietary modifications such as exclusion of gas- producing foods (eg, beans, prunes, Brussel sprouts, bagels, etc.), trials of gluten avoidance, and consumption of probiotics, as well as psychosocial therapies (eg, hypnosis, biofeedback, etc.) (Ford et al 2014).
    [Show full text]
  • 208854Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208854Orig1s000 SUMMARY REVIEW OND=Office of New Drugs OPQ=Office of Pharmaceutical Quality OPDP=Office of Prescription Drug Promotion OSI=Office of Scientific Investigations CDTL=Cross-Discipline Team Leader COA=Clinical Outcome Assessment CSS=Controlled Substance Staff DAAAP= Division of Anesthesia, Analgesia, and Addiction Products OSE= Office of Surveillance and Epidemiology DEPI= Division of Epidemiology DMEPA=Division of Medication Error Prevention and Analysis DPMH = Division of Pediatric and Maternal Health MHT=Maternal Health Team Quality Review Team DISCIPLINE REVIEWER BRANCH/DIVISION Drug Substance Joseph Leginus CDER/OPQ/ONDP/ DNDAPI/NDBII Drug Product Sarah Ibrahim CDER/OPQ/ONDP/ DNDPII/NDPBV Process Zhao Wang CDER/OPQ/OPF/ DPAI/PABI Microbiology Zhao Wang CDER/OPQ/OPF/ DPAI/PABI Facility Donald Lech CDER/OPQ/OPF/DIA/IABIII Biopharmaceutics Peng Duan CDER/OPQ/ONDP/ DB/BBII Regulatory Business Cheronda Cherry-France CDER/OND/ODEIII/ DGIEP Process Manager Application Technical Lead Hitesh Shroff CDER/OPQ/ONDP/ DNDPII/NDPBV Laboratory (OTR) N/A N/A ORA Lead Paul Perdue Jr. ORA/OO/OMPTO/ DMPTPO/MDTP Environmental Analysis James Laurenson CDER/OPQ/ONDP (EA) 2 Reference ID: 4073992 1. Benefit-Risk Assessment I concur with the reviewers’ conclusions that the benefit/risk of naldemedine is favorable in the population for which this product will be approved and that the risks can be managed with labeling. The applicant proposed the following indication for naldemedine, an orally administered peripheral mu opioid receptor antagonist: Symproic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
    [Show full text]